# Agent Capital

> Agent Capital is a VC fund in Cambridge backing Biotechnology and Health Care. See 53 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 53
- Last investment: May 2025
- Lead investor: 8%
- Last fund: Nov 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/agentcapital/
- Website: https://www.agentcapital.com/

Agent Capital is a VC fund in Cambridge focused on Biotechnology and Health Care. A biotech venture capital firm.

## Contacts

5 contacts available for Agent Capital. Shizune tracks 2 team members at Agent Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/agent-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 32 | 60% |
| Health Care | 22 | 42% |
| Therapeutics | 17 | 32% |
| Medical | 10 | 19% |
| Life Science | 9 | 17% |

24 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 18 | 34% |
| Series A | 11 | 21% |
| Series C | 7 | 13% |
| Funding Round | 6 | 11% |
| Seed | 4 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 33 | 62% |
| France | 1 | 2% |
| Switzerland | 1 | 2% |
| United Kingdom | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Geeta Vemuri | Co-Founder & Managing Partner | 13 | https://shizune.co/investors/profile/geeta-vemuri |
| Preston Noon | Co-Founder & General Partner | 1 | https://shizune.co/investors/profile/preston-noon-0c83 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GlycoEra | GlycoEra is a CustomGlycan platform that unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics. | $130M | Series B | May 27, 2025 |  |
| Hone Health | Hone treats men's hormone imbalances and low testosterone with at-home lab testing, physician consultations, and medication | $33M | Series A | Jan 28, 2025 |  |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M |  | Jan 01, 2025 |  |
| TRex Bio | TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $84M | Series B | Nov 13, 2024 |  |
| Foresight Diagnostics | Foresight Diagnostics develops novel technology created to detect cancers earlier from a simple blood draw. | $33M | Series B | Jul 30, 2024 |  |
| āshibio | āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course. | $40M | Series A | Jun 20, 2024 |  |
| Cerevance | Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, thecompany generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders. | $47M | Series B | Apr 25, 2024 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M |  | Mar 25, 2024 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $42M | Post-IPO Equity | Mar 25, 2024 |  |
| Cantai Therapeutics | Cantai Therapeutics operates as a developer of drug candidates. | $700K | Seed | Nov 20, 2023 |  |

10 of 53 investments shown.

## Co-investors
- [Penn Medicine Co-Investment Program](https://shizune.co/investors/profile/penn-medicine-co-investment-fund) — VC Fund, 8 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 8 deals together
- [Tellus BioVentures](https://shizune.co/investors/profile/tellus-bioventures) — VC Fund, 8 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 7 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 7 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 7 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Agent Capital invest in?

Agent Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 53 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Agent Capital?

Public channels for Agent Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Agent Capital?

The team at Agent Capital includes Geeta Vemuri (Co-Founder & Managing Partner) and Preston Noon (Co-Founder & General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co